Cambridge Lab Mistake Yields Light-Powered Reaction That Reverses 150 Years of Organic Chemistry
A failed control experiment led Cambridge chemists to discover a metal-free, LED-driven method for modifying drug molecules at positions previously considered unreachable, reversing the selectivity rules established by Friedel and Crafts in 1877.
Overview
A serendipitous laboratory mistake at the University of Cambridge has produced a new chemical reaction that inverts nearly 150 years of established organic chemistry. Published on March 12 in Nature Synthesis, the technique uses an ordinary LED lamp to forge carbon-carbon bonds on drug molecules at positions that conventional methods cannot reach, without requiring any metal catalysts or harsh conditions.
The discovery, which the team has named the “anti-Friedel-Crafts” reaction, emerged when PhD student David Vahey removed a photocatalyst from an experiment as a routine control test and found that the reaction not only still worked, but produced an entirely unexpected product.
What Happened in the Lab
Vahey, a researcher in Professor Erwin Reisner’s group at St John’s College, Cambridge, was investigating aldehyde-ketone coupling reactions when he decided to run a control experiment without the photocatalyst. Rather than shutting down as expected, the starting materials reacted on their own under blue LED light, producing an aromatic alkylation product instead of the anticipated coupling compound.
The result initially appeared to be an error. Rather than dismissing it, the team investigated the unexpected product and discovered something genuinely novel. “Recognizing the value in the unexpected is probably one of the key characteristics of a successful scientist,” Reisner told Phys.org.
How It Works
The traditional Friedel-Crafts reaction, first described by Charles Friedel and James Crafts in 1877, attaches carbon groups to electron-rich sites on electron-rich aromatic rings. It is one of the most widely used reactions in organic chemistry and pharmaceutical manufacturing.
The Cambridge reaction does the opposite. It targets electron-poor sites on electron-poor aromatic rings, a selectivity pattern that existing methods struggle to achieve. The reaction is mediated by a light-generated radical ion pair consisting of a bulky amine base and a redox-active phthalimide ester bearing the alkyl group, as described in Chemical & Engineering News. Blue LED light activates the transfer of the alkyl group to the aromatic ring, triggering a self-sustaining chain process at ambient temperature.
“This is far milder, and it does something completely different to established methods,” Vahey said, according to C&EN.
Why It Matters for Drug Development
The pharmaceutical implications are significant. Drug molecules are typically complex structures with multiple sensitive functional groups. When medicinal chemists need to test a small structural change, they often must rebuild large portions of the molecule from scratch, a process that can take months.
The anti-Friedel-Crafts reaction’s high functional-group tolerance allows targeted modifications during the final stages of drug development without disturbing sensitive regions of the molecule. The Cambridge team demonstrated this by successfully modifying several existing drug molecules, including the lipid-regulating medication gemfibrozil, as reported by Phys.org.
Computational chemist Max Garcia-Melchor at Trinity College Dublin developed a machine learning algorithm that can predict where the alkyl group will attach based on electron density indices, adding a predictive layer to the experimental work. Meanwhile, pharmaceutical partner AstraZeneca has already scaled the reaction to gram-scale production using flow chemistry systems, according to C&EN.
What We Don’t Know
Several questions remain open. The full scope of aromatic substrates compatible with the reaction has not yet been mapped, and it is unclear how broadly the technique will apply beyond the drug molecules tested so far. The machine learning model for predicting regioselectivity, while promising, will need validation across a wider chemical space. The AstraZeneca flow chemistry scale-up is still at an early stage, and the transition from gram-scale to industrial production could surface unforeseen challenges.
The longer-term question is whether the anti-Friedel-Crafts approach will integrate smoothly into existing pharmaceutical manufacturing pipelines, or whether it will require new infrastructure and workflows to deploy at scale.